Tenofovir Alafenamide 25 mg Tablets, offered by Kureasia Pharma, represent a modern advancement in antiviral therapy designed for the effective management of chronic viral infections such as HIV-1 and chronic hepatitis B (HBV). This formulation contains Tenofovir Alafenamide (TAF), a nucleotide reverse transcriptase inhibitor (NtRTI) that acts by blocking the activity of reverse transcriptase, an enzyme vital for viral replication. By inhibiting this enzyme, Tenofovir Alafenamide helps to reduce the viral load in the bloodstream, supports immune recovery, and slows the progression of infection, ultimately improving patient outcomes and quality of life.
Tenofovir Alafenamide is a prodrug of Tenofovir with enhanced pharmacological properties. Compared to its predecessor, Tenofovir Disoproxil Fumarate (TDF), it delivers higher intracellular concentrations of the active metabolite with significantly lower systemic exposure, thereby reducing the risk of renal and bone toxicity. This improved safety profile makes it particularly suitable for long-term therapy in patients requiring chronic antiviral treatment. The 25 mg dosage ensures optimal balance between efficacy and tolerability, allowing effective viral suppression with fewer side effects.
Each tablet is formulated to meet the highest standards of pharmaceutical quality, ensuring consistent potency, stability, and patient compliance. The tablets are easy to administer orally, generally taken once daily with or without food, as prescribed by a healthcare professional. Kureasia Pharma ensures that the product undergoes stringent quality control and adheres to international regulatory guidelines, reflecting its commitment to excellence, innovation, and patient care.
Tenofovir Alafenamide 25 mg Tablets are indicated as part of combination antiretroviral therapy for the treatment of HIV-1 infection in adults and adolescents weighing at least 35 kg, and for the treatment of chronic hepatitis B infection in adults with compensated liver disease. By maintaining suppression of viral replication, it helps prevent disease progression, reduce the risk of liver complications, and enhance immune system recovery.
With a focus on safety, efficacy, and affordability, Kureasia Pharma’s Tenofovir Alafenamide 25 mg Tablets are a reliable choice for healthcare professionals and patients alike. The product is developed using advanced manufacturing technology to ensure precise dosage delivery, purity, and therapeutic consistency. Through ongoing research and innovation, Kureasia Pharma continues to provide world-class pharmaceutical solutions to improve global health outcomes.
Key Features:
Contains Tenofovir Alafenamide 25 mg – a potent antiviral agent.
Enhanced efficacy with reduced renal and bone toxicity.
Once-daily oral administration for improved patient adherence.
Suitable for long-term management of HIV-1 and chronic hepatitis B.
Manufactured under strict GMP and WHO-compliant standards.
Kureasia Pharma is dedicated to providing high-quality, affordable, and innovative pharmaceutical products aimed at transforming healthcare and enhancing lives worldwide